RxDoctor Payments Data

Kenneth Dardick, MD

Family Medicine · Storrs, CTNPI 1316930266

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $130,614 of the $145,745 with a category attached, or 89.6%. 44 manufacturers reported payments, led by Valneva Austria GmbH at 57.3% of the total. Reporting peaked in 2019 at $43,308 and has fallen 54.6% since, to $19,678 in 2025. Among family medicine clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$145,745in general payments, 2019–2025

Across 282 payments — averaging $516.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Valneva Austria GmbH$83K
  • Pfizer$58K
  • Novo Nordisk$524
  • AstraZeneca$512
  • AbbVie$342
  • Lilly USA, LLC$335
  • plus $3K from 38 others

What the payments were for

  • Consulting fees$130,61490%
  • Travel & lodging$10,2857%
  • Food & beverage$4,8463%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$145,745 in reported general payments places this provider in the 95th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$53,207
Medicare patients
134
Services billed
831

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide81$162,589
EliquisApixaban59$88,274
JardianceEmpagliflozin55$66,887
FarxigaDapagliflozin Propanediol42$58,283
JanuviaSitagliptin Phosphate34$45,347
TrulicityDulaglutide16$25,253
XareltoRivaroxaban14$22,712
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$13,869
SymbicortBudesonide/Formoterol Fumarate17$9,687
AbrysvoRsv Vacc, Pref A And Pref B/Pf27$8,282
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$6,931
Sucralfate11$5,119
Bupropion XlBupropion Hcl27$4,685
ShingrixVaricella-Zoster Ge/As01b/Pf20$4,251
Atorvastatin Calcium534$3,475

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$524$162,58981 claims
PfizerEliquis, Abrysvo, Paxlovid$57,890$97,985117 claims
AstraZenecaFarxiga, Symbicort$512$67,97059 claims
Boehringer IngelheimJardiance$290$66,88755 claims
MerckJanuvia$271$45,34734 claims
Lilly USA, LLCTrulicity$335$25,25316 claims
Johnson & JohnsonXarelto$47$22,71214 claims
GSKTrelegy Ellipta, Shingrix$171$18,11936 claims
AbbVieSynthroid$342$2,84421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 588 family medicine providers in Connecticut.

Other family medicine in Storrs

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →